← Oncology Approval Tracker

FDA DECISION ·

Darzalex + Kyprolis + dexamethasone

daratumumab + carfilzomib + dexamethasone · Janssen Biotech and Onyx Pharmaceuticals

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after one to three previous lines of therapy.

LAMPGEN ANALYSIS

Why it matters

Added a proteasome inhibitor and anti-CD38 combination for relapsed or refractory myeloma.

What research teams should watch

Align carfilzomib and daratumumab schedules and review baseline cardiac function and transfusion needs.

PRIMARY RECORDS

Sources